Removal of azo dyes orange II and reactive black 5 from aqueous solutions by adsorption on chitosan beads modified with choline chloride: urea deep eutectic solvent and FeO

The removal of the azo dyes Orange II (OII) and Reactive Black 5 (RB5) from aqueous solutions was studied using three types of adsorbents derived from chitosan: unmodified chitosan beads (un-Ch), chitosan beads tuned with a deep eutectic solvent (DES) composed of choline chloride:urea at a 1:2 molar ratio (Ch-DES), along with FeO nanoparticles added to chitosan and modified with DES (Ch-FeO-DES). Both dyes were effectively removed in 3–4 h when Ch-DES beads were used, at a dye concentration range of 25–50 mg/L. The modification with DES improved the removal efficiency to achieve increases of around 32% for OII and 17% for RB5. The adsorbent dosage and the initial dye concentration influenced the adsorption process. Isotherm adsorption models (Langmuir, Freundlich, and Temkin) and kinetic models (pseudo-first-order, pseudo-second-order, intraparticle diffusion, and Elovich models) were applied to identify the adsorption behavior. The process could be characterized by employing the pseudo-second-order kinetic model and fitting it to the monolayer Langmuir isotherm. The adsorption occurred on a monolayer with no interaction among dye molecules when electrostatic forces would determine the attaching of dye molecules on the adsorbent. OII was efficiently desorbed by an alkaline solution, while RB5 was more strongly attached. The adsorbent could be recycled, after regeneration with an acid solution, for at least 5 reuse cycles while still achieving effective OII removal. Reactivation with a diluted EDTA solution allowed the authors to recycle RB5-attached beads, achieving optimum removal in two further uses.Xunta de Galicia | Ref. GPC-ED431B 2020/08Agencia Estatal de Investigación | Ref. PID2019-107728RB-I0

Removal of Acid Blue 80 from aqueous solutions using chitosan-based beads modified with choline chloride: urea Deep Eutectic Solvent and FeO

An alternative chitosan-based adsorbent modified by impregnation with deep eutectic solvent (DES) choline-chloride:urea at a molar ratio 1:2 proved efficient removal of the anthraquinone dye Acid Blue 80 (AB80) from aqueous solutions, and offered enhanced adsorption capacity compared to the starting materials. The adsorption was mainly affected by initial AB80 concentration, adsorbent dosage, contact time, and slightly influenced by temperature (25–45 °C), and pH (3.5–10). The pseudo-second-order kinetic model fitted the experimental data, and pseudo-first order model fitted as well at the highest AB80 concentration, 250 mg/L. The experimental data agreed with the Langmuir isotherm model, with a maximum adsorption capacity of 61.64 mg/g at 35 °C. The process was exothermic above 100 mg/L of dye and spontaneous up to 200 mg/L (T < 35 °C). The adsorbent could be reused without further treatment at least 5 times providing ≥40% removal, whereas the dye could be efficiently recovered by NaOH desorption. Electrostatic interactions as well as physisorption could explain the adsorption behaviorAgencia Estatal de Investigación | Ref. PID2019-107728RB-I00Xunta de Galicia | Ref. ED431B 2020/08Financiado para publicación en acceso aberto: Universidade de Vigo/CISU

Association Between Preexisting Versus Newly Identified Atrial Fibrillation and Outcomes of Patients With Acute Pulmonary Embolism

Background Atrial fibrillation (AF) may exist before or occur early in the course of pulmonary embolism (PE). We determined the PE outcomes based on the presence and timing of AF. Methods and Results Using the data from a multicenter PE registry, we identified 3 groups: (1) those with preexisting AF, (2) patients with new AF within 2 days from acute PE (incident AF), and (3) patients without AF. We assessed the 90-day and 1-year risk of mortality and stroke in patients with AF, compared with those without AF (reference group). Among 16 497 patients with PE, 792 had preexisting AF. These patients had increased odds of 90-day all-cause (odds ratio [OR], 2.81; 95% CI, 2.33-3.38) and PE-related mortality (OR, 2.38; 95% CI, 1.37-4.14) and increased 1-year hazard for ischemic stroke (hazard ratio, 5.48; 95% CI, 3.10-9.69) compared with those without AF. After multivariable adjustment, preexisting AF was associated with significantly increased odds of all-cause mortality (OR, 1.91; 95% CI, 1.57-2.32) but not PE-related mortality (OR, 1.50; 95% CI, 0.85-2.66). Among 16 497 patients with PE, 445 developed new incident AF within 2 days of acute PE. Incident AF was associated with increased odds of 90-day all-cause (OR, 2.28; 95% CI, 1.75-2.97) and PE-related (OR, 3.64; 95% CI, 2.01-6.59) mortality but not stroke. Findings were similar in multivariable analyses. Conclusions In patients with acute symptomatic PE, both preexisting AF and incident AF predict adverse clinical outcomes. The type of adverse outcomes may differ depending on the timing of AF onset.info:eu-repo/semantics/publishedVersio

Evolving trends in the management of acute appendicitis during COVID-19 waves. The ACIE appy II study

Background: In 2020, ACIE Appy study showed that COVID-19 pandemic heavily affected the management of patients with acute appendicitis (AA) worldwide, with an increased rate of non-operative management (NOM) strategies and a trend toward open surgery due to concern of virus transmission by laparoscopy and controversial recommendations on this issue. The aim of this study was to survey again the same group of surgeons to assess if any difference in management attitudes of AA had occurred in the later stages of the outbreak. Methods: From August 15 to September 30, 2021, an online questionnaire was sent to all 709 participants of the ACIE Appy study. The questionnaire included questions on personal protective equipment (PPE), local policies and screening for SARS-CoV-2 infection, NOM, surgical approach and disease presentations in 2021. The results were compared with the results from the previous study. Results: A total of 476 answers were collected (response rate 67.1%). Screening policies were significatively improved with most patients screened regardless of symptoms (89.5% vs. 37.4%) with PCR and antigenic test as the preferred test (74.1% vs. 26.3%). More patients tested positive before surgery and commercial systems were the preferred ones to filter smoke plumes during laparoscopy. Laparoscopic appendicectomy was the first option in the treatment of AA, with a declined use of NOM. Conclusion: Management of AA has improved in the last waves of pandemic. Increased evidence regarding SARS-COV-2 infection along with a timely healthcare systems response has been translated into tailored attitudes and a better care for patients with AA worldwide

Impact of COVID-19 on cardiovascular testing in the United States versus the rest of the world

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-US institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection

Centrality evolution of the charged-particle pseudorapidity density over a broad pseudorapidity range in Pb-Pb collisions at root s(NN)=2.76TeV

Peer reviewe

Desarrollo de métodos y evaluación de los niveles de dioxinas, PCBs "dioxin-like", compuestos bromados, organoestánnicos y metales pesados en productos y subproductos de la pesca y acuicultura

Esta Tesis Doctoral aborda el desarrollo de metodología analítica, fundamentalmente técnicas cromatográficas acopladas a la detección mediante espectrometría de masas en trampa iónica (GC-ITMS), para contaminantes químicos: dioxinas y furanos, PCBs "dioxin-like" y PBDEs. La medición de los niveles de estos contaminantes orgánicos y de metales pesados mediante espectrometría de absorción atómica se realiza en productos y/o subproductos de la pesca y de la acuicultura. Se evaluó la transferencia de contaminantes lipofílicos a rodaballos de cultivo a partir de los piensos con que fueron alimentados. Por último, se ha realizado el estudio de la toxicidad in vitro de los compuestos organoestánnicos (OTCs) en líneas celulares humanas y se presentan los resultados preliminares en relación al desarrollo de un método de screening basado en el mecanismo de acción de estos compuestos. Los principales resultados obtenidos fueron: 1. Se desarrolló un método de análisis de dioxinas y policlorobifenilos "dioxin-like", mediante GC-ITMS, adecuado para su aplicación rutinaria en productos de la pesca y acuicultura. Los contenidos en productos de la pesca fueron inferiores al límite legislado, con la excepción de muestras puntuales de naturaleza grasa, hígado y aceite de pescado. 2. Se desarrolló un método de análisis simultáneo de 26 congéneres de polibromodifenil éteres di- a deca-bromados en productos de la pesca y acuicultura y en piensos, harinas y aceites de pescado, mediante la combinación de técnicas automatizadas de purificación y fraccionamiento de los extractos y el procesado instrumental GC-ITMS optimizadas conjuntamente. 3. Las concentraciones de metales pesados en pescados y mariscos se mantienen en niveles "seguros" conforme a la legislación europea, con algunas excepciones en peces depredadores con elevado contenido en mercurio, cadmio en moluscos cefalópodos y cadmio y plomo en algunas especies de moluscos bivalvos. 4. Los contaminantes lipofílicos PCDD/Fs, dl-PCBs y PBDEs en los piensos de acuicultura utilizados en este estudio se reflejan en los filetes de rodaballo, tanto en perfiles como en concentraciones. Los valores de PCDD/Fs y dl-PCBs hallados en piensos y rodaballos fueron inferiores a los legislados, y los de PBDEs, del mismo orden que los descritos a nivel internacional. 5. Los dl-PCBs, y los PBDEs tri-, tetra-, penta-, y hexa-bromados, y los PCDD/Fs tetra- y penta-clorados fueron los más eficazmente acumulados por los rodaballos. 6. Se observó biomagnificación de la mayor parte de PCDD/Fs, dl-PCBs y PBDEs. La elevada acumulación del BDE-49 se debe muy posiblemente a la contribución del metabolismo de los congéneres con mayor grado de bromación. 7. Los compuestos organoestánnicos dibutilestaño (DBT) y tributilestaño (TBT) ejercen un efecto tóxico in vitro en células tumorales de neuroblastoma humano, que involucra diferentes rutas dependiendo del compuesto, su concentración y su caracter lipofílico, induciendo muerte celular por los mecanismos de necrosis y apoptosis. 8. El ensayo de viabilidad celular AlamarBlue permite establecer un método de cuantificación de DBT y TBT, ofreciendo una alternativa más económica a los análisis instrumentales. 9. Es necesario realizar un control continuado de contaminantes lipofílicos y metales pesados en productos de la pesca y acuicultura para mantener la seguridad del consumidor

Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study

We investigated differences in mpox clinical outcomes in people with HIV (PWH) and without HIV (PWoH) and the impact of vaccination in Catalonia, Spain. We used surveillance data and the PISCIS HIV cohort. We included all confirmed mpox cases (May–December 2022). Of 2122 mpox cases, the majority had mild disease, 56% were Spanish, and 24% were from Latin America. A total of 40% were PWH, with a median CD4+T-cell of 715 cells/μL; 83% had HIV-RNA p = 0.001). Diagnosis of other sexually transmitted infections (STIs) was common, both at mpox diagnosis (17%) and two years before (43%). Dose-sparing smallpox intradermal vaccination was accompanied by a sharp decrease in mpox incidence in both populations (p < 0.0001). In conclusion, unless immunosuppressed, PWH were not at increased risk of severe disease or hospitalization. Mpox is a marker of high-risk sexual behavior and was associated with high HIV and STI rates, supporting the need for screening in all mpox cases. Ethnicity disparities demonstrate the need for interventions to ensure equitable healthcare access. Dose-sparing smallpox vaccination retained effectiveness

Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry

International audienceImportance: Insufficient data exist about the clinical presentation, short-term, and long-term outcomes of patients with isolated distal deep vein thrombosis (IDDVT), that is, thrombosis in infrapopliteal veins without proximal extension or pulmonary embolism (PE).Objective: To determine the clinical characteristics, short-term, and 1-year outcomes in patients with IDDVT and to compare the outcomes in unadjusted and multivariable adjusted analyses with patients who had proximal DVT.Design, setting, and participants: This was a multicenter, international cohort study in participating sites of the Registro Informatizado Enfermedad Tromboembólica (RIETE) registry conducted from March 1, 2001, through February 28, 2021. Patients included in this study had IDDVT. Patients with proximal DVT were identified for comparison. Patients were excluded if they had a history of asymptomatic DVT, upper-extremity DVT, coexisting PE, or COVID-19 infection.Main outcomes and measures: Primary outcomes were 90-day and 1-year mortality, 1-year major bleeding, and 1-year venous thromboembolism (VTE) deterioration, which was defined as subsequent development of proximal DVT or PE.Results: A total of 33 897 patients were identified with isolated DVT (without concomitant PE); 5938 (17.5%) had IDDVT (mean [SD] age, 61 [17] years; 2975 male patients [50.1%]), and 27 959 (82.5%) had proximal DVT (mean [SD] age, 65 [18] years; 14 315 male patients [51.2%]). Compared with individuals with proximal DVT, those with IDDVT had a lower comorbidity burden but were more likely to have had recent surgery or to have received hormonal therapy. Patients with IDDVT had lower risk of 90-day mortality compared with those with proximal DVT (odds ratio [OR], 0.47; 95% CI, 0.40-0.55). Findings were similar in 1-year unadjusted analyses (hazard ratio [HR], 0.52; 95% CI, 0.46-0.59) and adjusted analyses (HR, 0.72; 95% CI, 0.64-0.82). Patients with IDDVT had a lower 1-year hazard of VTE deterioration (HR, 0.83; 95% CI, 0.69-0.99). In 1-year adjusted analyses of patients without an adverse event within the first 3 months, IDDVT was associated with lower risk of VTE deterioration (adjusted HR, 0.48; 95% CI, 0.24-0.97). By 1-year follow-up, symptoms or signs of postthrombotic syndrome were less common in patients with IDDVT (47.6% vs 60.5%).Conclusions and relevance: Results of this cohort study suggest that patients with IDDVT had a less ominous prognosis compared with patients with proximal DVT. Such differences were likely multifactorial, including the differences in demographics, risk factors, comorbidities, particularly for all-cause mortality, and a potential association of thrombus location with VTE deterioration and postthrombotic syndrome. Randomized clinical trials are needed to assess the optimal long-term management of IDDVT

Impact of COVID-19 on Cardiovascular Testing in the United States Versus the Rest of the World

Objectives: This study sought to quantify and compare the decline in volumes of cardiovascular procedures between the United States and non-U.S. institutions during the early phase of the coronavirus disease-2019 (COVID-19) pandemic. Background: The COVID-19 pandemic has disrupted the care of many non-COVID-19 illnesses. Reductions in diagnostic cardiovascular testing around the world have led to concerns over the implications of reduced testing for cardiovascular disease (CVD) morbidity and mortality. Methods: Data were submitted to the INCAPS-COVID (International Atomic Energy Agency Non-Invasive Cardiology Protocols Study of COVID-19), a multinational registry comprising 909 institutions in 108 countries (including 155 facilities in 40 U.S. states), assessing the impact of the COVID-19 pandemic on volumes of diagnostic cardiovascular procedures. Data were obtained for April 2020 and compared with volumes of baseline procedures from March 2019. We compared laboratory characteristics, practices, and procedure volumes between U.S. and non-U.S. facilities and between U.S. geographic regions and identified factors associated with volume reduction in the United States. Results: Reductions in the volumes of procedures in the United States were similar to those in non-U.S. facilities (68% vs. 63%, respectively; p = 0.237), although U.S. facilities reported greater reductions in invasive coronary angiography (69% vs. 53%, respectively; p < 0.001). Significantly more U.S. facilities reported increased use of telehealth and patient screening measures than non-U.S. facilities, such as temperature checks, symptom screenings, and COVID-19 testing. Reductions in volumes of procedures differed between U.S. regions, with larger declines observed in the Northeast (76%) and Midwest (74%) than in the South (62%) and West (44%). Prevalence of COVID-19, staff redeployments, outpatient centers, and urban centers were associated with greater reductions in volume in U.S. facilities in a multivariable analysis. Conclusions: We observed marked reductions in U.S. cardiovascular testing in the early phase of the pandemic and significant variability between U.S. regions. The association between reductions of volumes and COVID-19 prevalence in the United States highlighted the need for proactive efforts to maintain access to cardiovascular testing in areas most affected by outbreaks of COVID-19 infection.</p